Trials / Completed
CompletedNCT04077424
Senescent Immunity in Elders and Vaccine Responses (SILVER)
Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Vanderbilt University Medical Center · Academic / Other
- Sex
- All
- Age
- 65 Years – 125 Years
- Healthy volunteers
- Accepted
Summary
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Fluzone-High Dose Quadrivalent | Seasonal influenza vaccination with FDA approved vaccines for this age group. |
| BIOLOGICAL | Fluad | Adjuvanted (MF59) inactivated influenza vaccine |
| BIOLOGICAL | Flublock | Recombinant hemagglutinin vaccine |
Timeline
- Start date
- 2019-10-21
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
- First posted
- 2019-09-04
- Last updated
- 2022-07-12
- Results posted
- 2022-07-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04077424. Inclusion in this directory is not an endorsement.